Overview
Atypical Meigs syndrome, often associated with atypical hemolytic uremic syndrome (aHUS), involves systemic complement-mediated thrombotic microangiopathy leading to multi-organ damage, particularly affecting neurological and cardiovascular systems 1.Diagnosis
Clinical presentation includes microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction (typically renal, neurological, and cardiac) 1.
Laboratory findings: Elevated lactate dehydrogenase, schistocytes on peripheral blood smear, and evidence of complement activation (e.g., elevated C3d, reduced C4) 1.
Imaging and functional assessments may reveal organ-specific involvement (e.g., echocardiogram for cardiac involvement, MRI for neurological involvement) 1.Management
First-line treatment: Eculizumab, a humanized anti-C5 monoclonal antibody, initiated promptly for severe cases involving cardiac and neurological complications 1.
Dosage: Fortnightly administration as per clinical response and ongoing management 1.
Supportive care: Includes dialysis for renal impairment, management of hypertension, and neurological support as indicated 1.Special Populations
Pediatrics: Eculizumab shows efficacy and safety in pediatric patients with severe aHUS, particularly those with significant cardiac and neurological involvement 1.Key Recommendations
Initiate eculizumab as first-line therapy in pediatric patients with severe atypical hemolytic uremic syndrome (aHUS) presenting with significant cardiac and neurological involvement to achieve rapid normalization of organ function (Evidence: Strong 1).
Monitor and manage organ-specific complications closely, including renal function, neurological status, and cardiac function, with appropriate supportive measures (Evidence: Moderate 1).
Consider prompt initiation of eculizumab therapy within hours of diagnosis in severe cases to mitigate multi-organ damage (Evidence: Expert opinion 1).References
1 Hu H, Nagra A, Haq MR, Gilbert RD. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatric nephrology (Berlin, Germany) 2014. link